Amgen Procrit Epoetin Alfa Vials Recall: Visible Glass Flakes Hazard
Amgen recalls Procrit Epoet: 40,000 units/mL vials with visible glass flakes that could cause injury during injection. Check NDC 59676-340-01, lots G290491A/B, expiring 06/18.
Stop using this now
Presence of particulate matter: Visible glass flakes identified as lamellae in some drug product vials.
Contact the company
What happened, in plain English
Amgen recalls Procrit Epoetin Alfa vials that contain visible glass flakes. These flakes could cause injury if injected, so affected users should stop using the vials immediately. Read more at govinfonow.com/recall/41412-amgen-procrit-epoetin-alfa-vials-recall-visible-glass-flakes-hazard.
Source Summary by GovInfoNow · govinfonow.com/recall/41412-amgen-procrit-epoetin-alfa-vials-recall-visible-glass-flakes-hazard · Updated October 7, 2026 · FDA enforcement record: FDA #D-1086-2017
Cite this page
“Amgen Procrit Epoetin Alfa Vials Recall: Visible Glass Flakes Hazard.” GovInfoNow, updated October 7, 2026. https://govinfonow.com/recall/41412-amgen-procrit-epoetin-alfa-vials-recall-visible-glass-flakes-hazard. Based on FDA recall #D-1086-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1086-2017%22&limit=1).
Why it’s dangerous
Visible glass flakes in the vials can cause injury when injected into the body. This is a serious hazard because the flakes could puncture tissue or cause other complications during treatment.
Who’s affected
Patients prescribed Procrit Epoetin Alfa by a doctor who received vials with NDC 59676-340-01, lots G290491A or G290491B, expiring June 2018. Those using the vials for intravenous or subcutaneous injections are most at risk.
How to tell if you have this one
Check for vials labeled 'Procrit Epoetin Alfa 40,000 units/mL' with NDC code 59676-340-01. The specific lots are G290491A and G290491B, expiring June 2018.
- Brand
Amgen- Category
Drug
What to do — step by step
Stop Using Vials Now
Immediately stop using any vials with NDC 59676-340-01 and lots G290491A or G290491B.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “United States including Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 8 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Amgen recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1086-2017 (August 4, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1086-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 7, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.